A Study of LY2623091 in Participants With High Blood Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Primary Hypertension
Interventions
DRUG

LY2623091

Administered orally

DRUG

Tadalafil

Administered orally

DRUG

Spironolactone

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (43)

14609

Rochester Clinical Research, Inc., Rochester

27408

PharmQuest, Greensboro

28204

Metrolina Internal Medicine, P.A., Charlotte

29651

Mountain View Clinical Research, Inc, Greer

32216

Jacksonville Center for Clinical Research, Jacksonville

32720

Avail Clinical Research LLC, DeLand

33308

Alan Graff, MD, PA, Fort Lauderdale

34239

Cardiovascular Center of Sarasota, Sarasota

43213

Columbus Clinical Research, Columbus

44122

Rapid Medical Research Inc, Cleveland

45219

Sterling Research Group, LTD, Cincinnati

45406

Dayton Clinical Research, Dayton

46260

Midwest Institute for Clinical Research, Indianapolis

47304

Community Clinical Research Center, Muncie

58103

Lillestol Research LLC, Fargo

60005

Northwest Heart Clinical Research, LLC, Arlington Heights

60607

Cedar-Crosse Research Center, Chicago

67207

Heartland Research Associates, Wichita

71111

Grace Research, Bossier City

73120

Oklahoma Foundation For Cardiovascular Research, Oklahoma City

78681

Texas Diabetes and Endocrinology, P.A., Round Rock

78745

Tekton Research, Inc, Austin

83404

Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls

85306

Clinical Research Advantage, Glendale

89119

AB Clinical Trials, Las Vegas

92024

Encompass Clinical Research, Encinitas

94520

John Muir Health Network - The Osteoporosis Center, Concord

96814

East West Medical Institute, Honolulu

98405

Universal Research Group, LLC, Tacoma

4052728481

Cor Clinical Research LLC, Oklahoma City

04210

Maine Research Associates, Auburn

78731-4309

Texas Diabetes and Endocrinology, Austin

98007-4209

Northwest Clinical Research Center, Bellevue

L6T 0G1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brampton

V1Y3G8

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna

K9J 0B2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough

H9R 4S3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pointe-Claire

G1N 4V3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Québec

T4N 6V7

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Deer

J1J 2G2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke

M9W 4L6

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto

00717-1322

Research and Cardiovascular Corp., Ponce

00909

Clinical Research Puerto Rico, Inc., San Juan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02194465 - A Study of LY2623091 in Participants With High Blood Pressure | Biotech Hunter | Biotech Hunter